13G Filing: James E. Flynn and Audentes Therapeutics Inc (BOLD)

Page 3 of 18

Page 3 of 18 – SEC Filing

CUSIP No.
05070R104
13G
Page 3 of 15 
1.
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Deerfield Mgmt III, L.P.
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
  (a) o
  (b) ý
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware


NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
SOLE VOTING POWER
 
0
6.
SHARED VOTING POWER
 
889,230 (2)
7.
SOLE DISPOSITIVE POWER
 
0
8.
SHARED DISPOSITIVE POWER
 
889,230 (2)
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
889,230 (2)
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
o
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
 
3.21%
12.
TYPE OF REPORTING PERSON*
 
PN
__________________

(2) Comprised of Common Stock held by Deerfield Private Design Fund III, L.P., of which Deerfield Mgmt III, L.P. is the general
partner.

Follow Audentes Therapeutics Inc. (NASDAQ:BOLD)

Page 3 of 18